Sigyn Therapeutics (OTCMKTS:SIGY) Announces Earnings Results

Sigyn Therapeutics (OTCMKTS:SIGY) posted its quarterly earnings results on Thursday. The company reported ($0.42) earnings per share (EPS) for the quarter, Zacks reports.

Sigyn Therapeutics Stock Performance

Shares of Sigyn Therapeutics stock opened at $0.04 on Friday. The business has a 50-day simple moving average of $0.04 and a 200-day simple moving average of $0.29. Sigyn Therapeutics has a one year low of $0.01 and a one year high of $5.00. The company has a market cap of $101,600.00, a PE ratio of -0.01 and a beta of -0.08.

Sigyn Therapeutics Company Profile

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.